Spinocerebellar Ataxia Type 6
12
2
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Pivotal Study of N-acetyl-L-leucine for CACNA1A
Deep Brain Stimulation for Spinocerebellar Ataxia
Interposed Nucleus aDBS for Ataxia
Troriluzole in Adult Participants With Spinocerebellar Ataxia
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Instrumented Data Exchange for Ataxia Study
Open Pilot Trial of BHV-4157
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Study of CAD-1883 for Spinocerebellar Ataxia
Parkinsonism in Spinocerebellar Ataxia Type 6